Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.77 |
| ▸ | ABCB11 | O95342 | 4/20 | 0.77 |
| ▸ | ABCC4 | O15439 | 3/20 | 0.77 |
| ▸ | ABCC2 | Q92887 | 3/20 | 0.77 |
| ▸ | GAA | P10253 | 3/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.77 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.77 |
| ▸ | MEN1 | O00255 | 2/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.77 |
| ▸ | ABCC3 | O15438 | 2/20 | 0.77 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.77 |
| ▸ | SLCO2B1 | O94956 | 2/20 | 0.77 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.77 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.77 |
| ▸ | SLCO1A2 | P46721 | 2/20 | 0.77 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.77 |
| ▸ | SLCO1B1 | Q9Y6L6 | 2/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29625757 | 0.90 | MAPT (0.80) | MAPTABCB11ABCC4ABCC2GAA | |
| SCHEMBL23541652 | 0.90 | MAPT (0.83) | MAPTABCB11ABCC4ABCC2GAA | |
| SCHEMBL23510705 | 0.90 | MAPT (0.83) | MAPTABCB11ABCC4ABCC2GAA | |
| SCHEMBL23594215 | 0.90 | ABCB11 (0.83) | MAPTABCB11ABCC4ABCC2GAA | |
| SCHEMBL29559659 | 0.90 | ABCB11 (0.83) | MAPTABCB11ABCC4ABCC2GAA | |
| SCHEMBL23541658 | 0.90 | ABCB11 (0.83) | MAPTABCB11ABCC4ABCC2GAA | |
| SCHEMBL30988931 | 0.90 | MAPT (0.81) | MAPTABCB11ABCC4ABCC2GAA | |
| SCHEMBL30483221 | 0.89 | ABCB11 (0.75) | MAPTABCB11ABCC4ABCC2GAA | |
| SCHEMBL16273790 | 0.89 | MAPT (0.77) | MAPTABCB11ABCC4ABCC2GAA | |
| SCHEMBL14356353 | 0.88 | ABCB11 (0.80) | MAPTABCB11ABCC4ABCC2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169680-A1 | CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN | INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2022-06-02 | — | — | US | claimed |
| EP-3912989-A1 | CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN | Institute of Basic Medical Sciences Chinese Academy of Medical Sciences (CN) | 2021-11-24 | — | — | EP | claimed |
| US-10377779-B2 | Carbonate prodrugs and methods of using the same | ACORDA THERAPEUTICS, INC. (US) | 2019-08-13 | — | — | US | claimed |
| US-20180086778-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | NEUROGESX, INC. | 2018-03-29 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20130252945-A1 | AMORPHOUS BIOINORGANIC IONIC LIQUID COMPOSITIONS COMPRISING PHARMACEUTICALS | LOS ALAMOS NAT SECURITY LLC (US) | 2013-09-26 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-20120093759-A1 | Medical Devices, Wound Dressings, and Methods for Dressing Wounds | VACHON DAVID J (US) | 2012-04-19 | — | — | US | claimed |
| US-20110212927-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | NEUROGESX, INC. (US) | 2011-09-01 | — | — | US | claimed |
| CN-102149282-A | Carbonate prodrugs and methods of using the same | NEUROGESX INC | 2011-08-10 | — | — | CN | claimed |
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA | 2007-04-26 | — | — | US | claimed |
| WO-2007044693-A2 | MULTI-FUNCTIONAL IONIC LIQUID COMPOSITIONS | THE UNIVERSITY OF ALABAMA (US) | 2007-04-19 | — | — | WO | claimed |
| CN-1826129-A | Methods and compositions relating to isoleucine boroproline compounds | POINT THERAPEUTICS INC (US) | 2006-08-30 | — | — | CN | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-1578434-A2 | METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS | Point Therapeutics, Inc. (US) | 2005-09-28 | — | — | EP | claimed |
| US-20040131628-A1 | Nucleic acids for the treatment of disorders associated with microorganisms | BRATZLER ROBERT L (US) | 2004-07-08 | — | — | US | claimed |
| US-20040077601-A1 | Methods and compositions relating to isoleucine boroproline compounds | POINT THERAPEUTICS, INC. | 2004-04-22 | — | — | US | claimed |
| WO-2004004658-A2 | METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS | POINT THERAPEUTICS, INC. (US) | 2004-01-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | SLC5A6, PNLIP, IPMK | MAPT 4156/4885ABCB11 40/4885ABCC4 320/4885 |
| US-20110212927-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | CA6, CA7, CA4 | MAPT 3060/4885ABCB11 941/4885ABCC4 1418/4885 |
| US-10377779-B2 | Carbonate prodrugs and methods of using the same | CA6, CA7, CA4 | MAPT 3060/4885ABCB11 941/4885ABCC4 1418/4885 |
| US-20130252945-A1 | AMORPHOUS BIOINORGANIC IONIC LIQUID COMPOSITIONS COMPRISING PHARMACEUTICALS | MCOLN1, PYM1, MCOLN2 | MAPT 306/4885ABCB11 125/4885ABCC4 192/4885 |
| US-20180086778-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | CA6, CA7, CA4 | MAPT 3060/4885ABCB11 941/4885ABCC4 1418/4885 |
| US-20040077601-A1 | Methods and compositions relating to isoleucine boroproline compounds | BCAT1, BCAT2, APOB | MAPT 3727/4885ABCB11 173/4885ABCC4 3162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.